Caribou Biosciences, Inc. Research and Development Expense
Caribou Biosciences, Inc. (CRBU) reported Research and Development Expense of $18.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Caribou Biosciences, Inc. research and development expense for the quarter ending 2026-06-30 was $18.94M, a 31.60% decline year-over-year.
- Caribou Biosciences, Inc. research and development expense for the quarter ending 2026-03-31 was $20.61M, a 41.99% decline year-over-year.
- Caribou Biosciences, Inc. research and development expense for the quarter ending 2025-12-31 was $23.82M, a 21.83% decline year-over-year.
- Caribou Biosciences, Inc. research and development expense for the quarter ending 2025-09-30 was $22.40M, a 26.36% decline year-over-year.
- Caribou Biosciences, Inc. research and development expense for fiscal 2025 was $109.44M, a 15.92% decline from fiscal 2024.
- Caribou Biosciences, Inc. research and development expense for fiscal 2024 was $130.15M, a 16.13% increase from fiscal 2023.
- Caribou Biosciences, Inc. research and development expense for fiscal 2023 was $112.08M, a 36.29% increase from fiscal 2022.
- Caribou Biosciences, Inc. research and development expense for fiscal 2022 was $82.23M, a 57.36% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.94M 10-Q · filed 2026-08-13 | $39.55M 10-Q · filed 2026-08-13 | $63.37M derived: sum of 3 quarters · filed 2026-08-13 | $85.77M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $20.61M 10-Q · filed 2026-05-07 | $44.43M derived: sum of 2 quarters · filed 2026-05-07 | $66.83M derived: sum of 3 quarters · filed 2026-05-07 | $94.52M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $23.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $46.22M derived: sum of 2 quarters · filed 2026-03-05 | $73.91M derived: sum of 3 quarters · filed 2026-08-13 | $109.44M 10-K · filed 2026-03-05 |
| 2025-09-30 | $22.40M 10-Q · filed 2025-11-12 | $50.09M derived: sum of 2 quarters · filed 2026-08-13 | $85.62M 10-Q · filed 2025-11-12 | $116.09M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $27.69M 10-Q · filed 2026-08-13 | $63.22M 10-Q · filed 2026-08-13 | $93.69M derived: sum of 3 quarters · filed 2026-08-13 | $124.11M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $35.53M 10-Q · filed 2026-05-07 | $66.00M derived: sum of 2 quarters · filed 2026-05-07 | $96.42M derived: sum of 3 quarters · filed 2026-05-07 | $131.90M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $30.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $60.88M derived: sum of 2 quarters · filed 2026-03-05 | $96.36M derived: sum of 3 quarters · filed 2026-03-05 | $130.15M 10-K · filed 2026-03-05 |
| 2024-09-30 | $30.42M 10-Q · filed 2025-11-12 | $65.90M derived: sum of 2 quarters · filed 2025-11-12 | $99.69M 10-Q · filed 2025-11-12 | $130.97M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $35.48M 10-Q · filed 2025-08-12 | $69.27M 10-Q · filed 2025-08-12 | $100.55M derived: sum of 3 quarters · filed 2025-08-12 | $129.13M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $33.79M 10-Q · filed 2025-05-08 | $65.07M derived: sum of 2 quarters · filed 2025-05-08 | $93.65M derived: sum of 3 quarters · filed 2025-05-08 | $120.15M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $31.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $59.86M derived: sum of 2 quarters · filed 2025-03-10 | $86.37M derived: sum of 3 quarters · filed 2025-03-10 | $112.08M 10-K · filed 2025-03-10 |
| 2023-09-30 | $28.58M 10-Q · filed 2024-11-06 | $55.09M derived: sum of 2 quarters · filed 2024-11-06 | $80.80M 10-Q · filed 2024-11-06 | $106.53M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $26.50M 10-Q · filed 2024-08-06 | $52.21M 10-Q · filed 2024-08-06 | $77.95M derived: sum of 3 quarters · filed 2024-08-06 | $97.94M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $25.71M 10-Q · filed 2024-05-07 | $51.45M derived: sum of 2 quarters · filed 2024-05-07 | $71.44M derived: sum of 3 quarters · filed 2024-05-07 | $94.02M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $25.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $45.73M derived: sum of 2 quarters · filed 2024-03-11 | $68.31M derived: sum of 3 quarters · filed 2024-03-11 | $82.23M 10-K · filed 2024-03-11 |
| 2022-09-30 | $19.99M 10-Q · filed 2023-11-07 | $42.57M derived: sum of 2 quarters · filed 2023-11-07 | $56.49M 10-Q · filed 2023-11-07 | $71.61M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $22.58M 10-Q · filed 2023-08-08 | $36.50M 10-Q · filed 2023-08-08 | $51.61M derived: sum of 3 quarters · filed 2023-08-08 | $67.45M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $13.92M 10-Q · filed 2023-05-09 | $29.04M derived: sum of 2 quarters · filed 2023-05-09 | $44.87M derived: sum of 3 quarters · filed 2023-05-09 | $57.20M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $15.11M 10-K · filed 2022-03-21 | $30.94M derived: sum of 2 quarters · filed 2022-11-08 | $43.27M derived: sum of 3 quarters · filed 2022-11-08 | $52.26M 10-K · filed 2023-03-09 |
| 2021-09-30 | $15.83M 10-Q · filed 2022-11-08 | $28.16M derived: sum of 2 quarters · filed 2022-11-08 | $37.14M 10-Q · filed 2022-11-08 | $50.35M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $12.33M 10-Q · filed 2022-08-09 | $22.49M 10-Q · filed 2021-09-02 | $34.52M derived: sum of 3 quarters · filed 2022-08-09 | $40.70M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $10.16M 10-Q · filed 2022-05-09 | $22.19M derived: sum of 2 quarters · filed 2022-05-09 | $28.37M derived: sum of 3 quarters · filed 2022-05-09 | $35.95M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $12.02M 10-K · filed 2022-03-21 | $18.20M derived: sum of 2 quarters · filed 2022-03-21 | $25.78M derived: sum of 3 quarters · filed 2022-03-21 | $34.42M 10-K · filed 2022-03-21 |
| 2020-09-30 | $6.18M 10-K · filed 2022-03-21 | $13.76M derived: sum of 2 quarters · filed 2022-03-21 | $22.40M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $7.58M 10-K · filed 2022-03-21 | $16.22M 10-Q · filed 2021-09-02 | ||
| 2020-03-31 | $8.64M 10-K · filed 2022-03-21 | |||
| 2019-12-31 | $23.64M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |